Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Protocols / PTM Microarray: Request for Year 3 Set-Aside Funds

PTM Microarray: Request for Year 3 Set-Aside Funds

233

No involved investigator sites defined.

Post-translation modification for nitro-tyrosine and lipid peroxidation adducts on proteins secreted by the breast.
Proteomics
Breast and Gynecologic Cancers Research

We hypothesize that PTMs on proteins that are secreted by the breast will provide a more sensitive method for detecting breast cancer than analysis of the parent protein. We will antibody microarrays to have examine 9 circulating proteins, each of which is known to be actively secreted by the breast, for several structurally and functionally distinct PTMs. We will determine if these modified proteins have the potential to used in the early detection of breast cancer.

Aim 1) Develop antibody microarray chips that can be used to measure PTMs associated with glycosylation state or nTyr- or HNE-adducts. This chip will target abundant proteins we have identified in NAF that are also found in the circulation. Aim 2) Evaluate two sets of human plasma samples from women with and without breast cancer using the chips developed in Aim 1. The first set of samples is from the Clinical Breast Care Program (CBCP, samples collected at Walter Reed Army Medical Center) and contains 80 samples from control women or women with DCIS or stage 1 or 2 breast cancer. This set of samples will determine if these assays can detect early disease. The second set of samples will be from Dr. Jeff Marks (Duke University) and will contain 60 samples evenly split between three study groups: control women and women with Her2+/ER- tumor, and women with ER+/Her2- breast cancer. This set of samples will determine if these assays can detect both early- and late-stage disease as well as differentiate between different subtypes of cancer.
ELISA microarray

There are currently no biomarkers annotated for this protocol.

No datasets are currently associated with this protocol.


New Funding Opportunity: Biomarker Development Laboratories for the Early Detection Network: Applications Due May 23

Update: Pre-application webinar information now available.

The National Cancer Institute's Division of Cancer Prevention has released a new funding opportunity to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers.

The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this funding opportunity) should be focused on one or more of the following cancers: breast, prostate and other genitourinary organs, or lung. In addition, cancers with rapidly rising incidence rates, e.g., endometrial, hepatocellular, kidney, thyroid, oropharyngeal cancers, and/or cancers with unique etiology, e.g., mesothelioma, will be considered.

The newly funded units of the Early Detection Research Network will be announced later in April. Successful applicants have already been notified. Those researchers who were not successful during the last round of applications are encouraged to apply to this opportunity.